Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE)-Reference-Cited by-同舟云学术

Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE)

Published:2007-06 Issue:6 Volume:153 Page:960-969
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

Brieger David,Van de Werf Frans,Avezum Álvaro,Montalescot Gilles,Kennelly Brian M.,Granger Christopher B.,Goodman Shaun G.,Dabbous Omar H.,Agnelli Giancarlo

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference23 articles.

1. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non–Q-Wave Coronary Events Study Group;Cohen;N Engl J Med,1997

2. Platelet glycoprotein IIb/IIIa receptor inhibition in Non–ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention;Boersma;Circulation,1999

3. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban;Cannon;N Engl J Med,2001

4. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non–Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial;Antman;Circulation,1999

5. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: The ACUTE II study

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacologic Interactions;Cardiac Intensive Care;2019

2. Effect of age on efficacy and safety of vorapaxar in patients with non–ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial;American Heart Journal;2016-08

3. Age, treatment, and outcomes in high-risk non‐ST-segment elevation acute coronary syndrome patients: Insights from the EARLY ACS trial;International Journal of Cardiology;2013-09

4. Safety and Efficacy of Adjuvant Glycoprotein IIb/IIIa Inhibitors During Primary Percutaneous Coronary Intervention Performed From the Radial Approach for Acute ST Segment Elevation Myocardial Infarction;The American Journal of Cardiology;2013-06

5. ESC guidelines for the treatment of acute coronary syndromes in patients without persistent ST segment elevation at presentation. Task Force for the Treatment of Acute Coronary Syndromes (SCA) in Patients without Persistent Leveling of the ST Tract at the Presentation of the European Society of Cardiology (ESC);G ITAL CARDIOL;2012